Metabolic disease
Pre-approval drug surveillance
Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms
Clinical-note surveillance found rapidly growing use of products purported to contain retatrutide outside clinical trials. Compounded users lost 7.2% at six to twelve months versus 15.5% in trial participants, while early cardiovascular findings remain preliminary.
Leading the Conversation in Healthcare AI
Browse nference's publication below
Metabolic disease
Pre-approval drug surveillance
August 18, 2026
Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms
Clinical-note surveillance found rapidly growing use of products purported to contain retatrutide outside clinical trials. Compounded users lost 7.2% at six to twelve months versus 15.5% in trial participants, while early cardiovascular findings remain preliminary.
Neurology
Alzheimer’s prevention research
August 3, 2026
GLP-1–based incretin therapy is associated with lower incident Alzheimer’s disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk
In adults aged 50 or older with documented Alzheimer’s risk factors, a matched target-trial emulation found lower recorded Alzheimer’s incidence after GLP-1–based incretin initiation than after non-GLP-1 antidiabetic treatment. The observational design cannot establish prevention or causality.
Hepatology
Metabolic liver disease
August 3, 2026
Semaglutide is associated with stiffness improvement and broad liver benefits with distinct dose- and weight-linked patterns
Federated EHR and elastography analyses associated semaglutide exposure with lower liver stiffness and several longer-term liver outcomes, while separating dose-linked and weight-linked patterns.
Metabolic disease
Metabolic safety
July 20, 2026
New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching
In matched real-world cohorts, incident alopecia reached 4.20% with tirzepatide and 2.88% with semaglutide over twelve months—and remained higher after balancing achieved weight loss.
Infectious disease
Respiratory infection outcomes
July 17, 2026
Semaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection
Matched real-world comparisons found lower 30-day mortality, hospitalization, and composite severity after COVID-19 and influenza among semaglutide users than metformin comparators. The results are observational associations, not evidence that semaglutide prevents severe infection.
Metabolic disease
Geriatric metabolism
July 13, 2026
Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age Patients
An observational study of adults 65 and older linked higher achieved weight loss with more documented appetite loss, dehydration and malnutrition—signals for closer monitoring, not proof of causation.
Cardiovascular
Cardiometabolism
July 10, 2026
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss
In patients with existing cardiovascular disease, higher attained semaglutide dose was associated with lower later cardiovascular risk even when achieved weight loss was not.
Data science
Clinical data methods
June 24, 2026
Auditable large language model curation of clinical notes refines glucagon-like peptide-1 initiation, persistence ascertainment, and compounding use beyond prescription records
An evidence-linked LLM pipeline distinguished prescribing intent from documented medication use across more than 553,000 patients. At 18 months, prescription records produced materially higher persistence estimates than note-confirmed active use.
of 11
© 2026 nference, Inc. All rights reserved.